Please ensure Javascript is enabled for purposes of website accessibility

Why Evofem Biosciences Is Down Today

By Prosper Junior Bakiny – Jun 3, 2020 at 12:31PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company announced the pricing of a public offering of common stock.

What happened?

Evofem Biosciences (NASDAQ: EVFM), a small-cap biopharmaceutical company that focuses on developing products to address women's reproductive health needs, is plunging on the stock market on Wednesday, following the company's announcement of the pricing of a public offering of common stock after the market closed on Tuesday. Shares of Evofem Biosciences are down by 25.1% as of 11:17 a.m. EDT today.

So what

Evofem Biosciences intends to raise about $100 million via this public offering of common stock by selling 28.5 million at $3.50 a share. The company also gave underwriters the option to purchase an additional 4.275 million shares within 30 days. Note that before Evofem Biosciences announced the pricing of this public offering, its shares were going for approximately $6 apiece. Now, the company's stock price has dropped to about $3.46 apiece. With this public offering set to dilute Evofem Biosciences' existing shareholders, it's little wonder that investors aren't too happy.

Man with his hand on his forehead and a worried expression on his face, with a downward pointing graph in the background.

Image source: Getty Images.

Now what

Evofem Biosciences' stock has been volatile all year long, but the company recently received some great news. In late May, the Food and Drug Administration (FDA) approved Evofem's Phexxi, a prescription gel for the prevention of pregnancy. The healthcare company may be raising more funds to help launch its only FDA-approved product on the market, especially considering that as of March 31, Evofem only had $10.3 million in unrestricted cash and short-term investments. Evofem will likely remain highly volatile moving forward, but risk-tolerant investors will want to keep an eye on this one. 

Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
329%
 
S&P 500 Returns
106%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.